Lassa Fever Virus: Symptoms, Transmission, and Prevention

Lassa fever is a viral hemorrhagic disease caused by Lassa virus, a member of the Arenaviridae family, and it sickens an estimated 2.7 million people in West Africa each year. The virus lives quietly in rodent populations and spills over into humans through contact with contaminated food, surfaces, or bodily fluids. Most infections are mild or cause no symptoms at all, but a fraction progress to severe multi-organ disease with a fatality rate that can exceed 15 percent among hospitalized patients. Understanding how the virus moves, what it does to the body, and how communities can reduce their risk matters not only for people living in endemic regions but for global health systems preparing for the next outbreak.

The Virus and Its Rodent Hosts

Lassa virus is a single-stranded RNA virus roughly 110 to 130 nanometers across, wrapped in a protective envelope. It carries two segments of genetic material and comes in at least four recognized lineages that differ by as much as 27 percent at the genetic level.¹ That genetic diversity complicates vaccine design and diagnostic testing, because a tool built around one lineage may miss another.

The primary natural host is the Natal multimammate mouse, Mastomys natalensis, a small rodent that thrives in and around human homes across West Africa. Surveys in endemic communities found rodents inside more than 90 percent of houses, and Mastomys made up the majority of those trapped indoors.² The virus circulates persistently in these mice without making them visibly sick, and somewhere between 5 and 20 percent of Mastomys in endemic areas carry the virus at any given time.²

Mastomys is not the only host. Researchers have found Lassa virus in at least two other rodent species: the Guinea multimammate mouse (Mastomys erythroleucus) and the African wood mouse (Hylomyscus pamfi), both in Nigeria and Guinea.³ More recently, the rusty-bellied brush-furred mouse (Lophuromys sikapusi) was identified as a secondary reservoir in Sierra Leone.⁴ Field surveys during human outbreaks in Nigeria found all captured rodent genera, including Rattus, Crocidura, Mus, and Tatera, harboring the virus, sometimes at strikingly high rates.⁵ The broader the rodent reservoir, the harder the virus is to contain through any single control measure.

How People Get Infected

Most human infections come from contact with rodent urine and droppings. Dried excreta on floors, food stores, or household surfaces can become aerosolized when swept or disturbed. People can also pick up the virus by eating food contaminated by rodents, handling dead rodents, or breathing in particles in enclosed spaces where rodents live. In rural West Africa, where food is often stored in open containers and homes have porous walls and floors, daily life creates countless opportunities for exposure.

Human-to-human transmission also occurs, mainly through contact with the blood, urine, or other body fluids of an infected person. This route is especially dangerous in healthcare settings. A well-documented hospital cluster in Nigeria in 2018 began with a single 15-year-old patient who arrived with uncontrolled bleeding from the nose and throat. Sixteen healthcare workers became infected, five of them fatally, a case fatality rate of nearly 32 percent. Investigators traced the spread to a low index of suspicion for Lassa fever and inadequate infection prevention practices.⁶ A third of the confirmed healthcare worker cases were asymptomatic, meaning they could unknowingly pass the virus further.⁶

Seasonal Patterns and Why Outbreaks Peak in the Dry Season

In Nigeria, Lassa fever cases tend to peak in the first two to three months of the year, during the dry season. This pattern initially seems counterintuitive: modeling suggests that the number of infected rodents in the wild actually peaks around May and is at its lowest in December.⁷ So the peak in human cases does not simply track the peak in infected rodents. Researchers found that rainfall patterns were significantly correlated with human incidence, with the start and end of the high-exposure period roughly matching the start and end of the rainy season.⁷ The likely explanation is behavioral: as the dry season sets in and food becomes scarce outdoors, rodents migrate into homes seeking stored grain and water, increasing the contact rate between people and infected animals.

What the Illness Looks Like

Lassa fever presents across a wide spectrum, from entirely silent infections to fatal hemorrhagic disease.⁸ The majority of infections produce no noticeable symptoms or only a mild, flu-like illness with fever, fatigue, and general aches. Symptoms typically begin one to three weeks after exposure.

For the roughly 20 percent of infections that become clinically significant, the disease unfolds over stages. Early symptoms are maddeningly generic: fever, sore throat, headache, muscle pain, nausea, vomiting, and abdominal discomfort. These overlap almost perfectly with malaria, typhoid, and dengue, all of which circulate in the same regions. Co-infections complicate matters further. Studies in Nigeria have found that about 30 percent of children diagnosed with Lassa fever simultaneously had malaria parasites in their blood, and cases of co-infection with dengue and yellow fever have also been documented.⁹

When the disease progresses, symptoms escalate to facial swelling, fluid accumulation in the lungs, and bleeding from the mouth, nose, or gastrointestinal tract. The most common severe complications in a large case series included acute kidney injury (28 percent of cases), hepatitis (23 percent), and neurological problems such as meningitis or focal deficits (about 9 percent).¹⁰ Patients who died showed far higher markers of inflammation and more pronounced coagulopathy compared to survivors.¹⁰

How the Virus Damages the Body

Lassa virus enters cells by latching onto a sugar-coated protein on cell surfaces called dystroglycan, then slipping inside through a process related to macropinocytosis, a kind of cellular “gulping.”¹¹ Dystroglycan is found on cells throughout the body, which helps explain why the virus can infect so many different tissues.¹²

Once inside, the virus targets the endothelial cells that line blood vessels, as well as tissue macrophages and dendritic cells, key components of the immune system’s early-warning network. Infection of the blood vessel lining alone can cause low platelet counts, changes in vessel tone, and increased leakiness, which are the core features of hemorrhagic and edematous disease. Involvement of macrophages and dendritic cells then throws the broader immune response into disarray.¹³ The result is a two-track crisis: the vasculature leaks and clotting goes wrong, while the immune system either underreacts (failing to contain the virus) or overreacts (driving inflammatory damage to organs).

Hearing Loss After Recovery

One of the cruelest features of Lassa fever is what it leaves behind. Roughly one in three survivors develops sudden sensorineural hearing loss, either during late-stage illness or in early recovery.¹⁴ The hearing loss is often permanent. Animal models have shown that surviving mice develop lasting damage to the spiral ganglion cells of the auditory nerve and milder injury to the cochlear hair cells, consistent with the hearing loss observed in patients.¹⁵

The mechanism appears to be immune-mediated rather than a direct result of the virus destroying inner-ear tissue. Primate studies found severe vascular lesions consistent with systemic vasculitis in the inner ears and other tissues of survivors, along with persistent virus in brain tissue and autoimmune markers in the blood.¹⁶ In other words, the body’s own immune response to the virus may be what damages hearing, even after the acute infection has passed. This is significant because it suggests that future treatments aimed at preventing hearing loss would need to target the immune reaction, not just the virus itself.

Lassa Fever in Pregnancy

Pregnant women face dramatically worse outcomes. A prospective study found that women in their third trimester had an odds ratio for death of about 5.6 compared to women in the first two trimesters, and their risk was also substantially higher than that of non-pregnant women with the disease. Fetal and neonatal loss was devastating, reaching 87 percent.¹⁷ Evacuation of the uterus has historically been associated with improved maternal survival in severe cases, though the decisions involved are agonizing. The severity of Lassa fever in late pregnancy makes early recognition especially critical for this group.

Diagnosing Lassa Fever

The overlap between early Lassa symptoms and malaria, typhoid, and other febrile illnesses makes clinical diagnosis unreliable on its own. Laboratory confirmation is essential, and several testing methods exist: antigen detection, antibody tests for IgM and IgG, and PCR-based molecular assays. A systematic review of these diagnostic tools found that combined immunoassays that test for both IgM and antigens perform better than IgM alone, and that emerging rapid diagnostic tests show promise but need more field validation, particularly in the high temperatures common in West Africa.¹⁸ The diagnostic landscape is evolving, with active development of new molecular tests and multiplex assays that can distinguish Lassa from other hemorrhagic fevers in a single run.¹⁹

The practical problem in many endemic areas is not that the tests do not exist but that they are not available at the point of care. Secondary health facilities in outbreak regions frequently lack isolation rooms and routine access to diagnostic equipment, which delays both diagnosis and the protective measures needed to prevent spread.

Treatment and the Ribavirin Debate

For decades, the antiviral drug ribavirin has been considered the front-line treatment for Lassa fever. This reputation rests largely on a landmark 1986 trial, which reported that among patients with severely elevated liver enzymes, intravenous ribavirin given within six days of symptom onset reduced the fatality rate from 61 percent to just 5 percent.²⁰ Those numbers were striking enough to establish ribavirin as the standard of care.

However, that study has faced persistent scrutiny over its methods, and more recent assessments urge caution. A 2021 review argued that it is time to reconsider ribavirin’s role, noting that the methodological concerns about the original trial remain unresolved and that no subsequent randomized controlled trial has replicated the results.²¹ In practice, ribavirin is still used, especially in the absence of alternatives, but clinicians increasingly emphasize that aggressive supportive care, including fluid management, electrolyte correction, and organ support, may matter as much as or more than the antiviral itself. The evidence base for Lassa treatment remains thinner than you might expect for a disease that affects millions.

Prevention at the Community Level

Because most infections come from rodent contact, community-level rodent control is the most direct prevention strategy. A four-year field study in Upper Guinea tested a holistic approach combining chemical rodent treatment, trapping, environmental hygiene, house repairs, and rodent-proof food storage. The researchers found that chemical treatment effectively reduced local rodent populations and concluded that a layered strategy was both effective and well-accepted by communities.²² Practical steps include:

Food storage: Keeping grains, dried fish, and other staples in sealed containers or raised granaries that rodents cannot reach.
Home maintenance: Filling gaps in walls, roofs, and floors through which rodents enter.
Sanitation: Clearing refuse, cutting tall grass around homes, and avoiding leaving food scraps accessible.
Rodent reduction: Using traps and approved rodenticides, especially before and during the dry season when rodent migration indoors increases.

None of these steps alone is sufficient. The diversity of rodent species capable of carrying the virus means that even aggressive trapping of one species leaves others. The layered approach is what works.

Protecting Healthcare Workers

Nosocomial transmission is a recurring theme in Lassa fever outbreaks, and the gap between recommended infection control practices and what actually happens on the ground is wide. During a 2018 outbreak in Ondo State, Nigeria, surveys of healthcare workers found that while gloves were available to more than 90 percent of respondents, only about 42 percent always had face masks available, only 30 percent had goggles, and just 37 percent always had access to full-body personal protective equipment. None of the secondary health facilities surveyed had an isolation room.²³ The World Health Organization recommends a full suite of barrier protection for managing suspected cases, but limited budgets make implementation difficult in many facilities.²⁴

Knowledge levels among healthcare workers are generally high for basics like the causative agent and how to wear protective equipment, but the knowledge does not always translate into practice when supplies are absent.²⁵ The 2018 nosocomial cluster that killed five healthcare workers underscores what happens when suspicion is low and supplies are short: the virus can race through a ward before anyone realizes what they are dealing with.

Vaccine Development

No licensed vaccine for Lassa fever exists yet, but several candidates are in human trials. Four vaccines have entered the clinical stage of development: INO-4500, MV-LASV, rVSVΔG-LASV-GPC, and EBS-LASV. As of a recent scoping review, five phase 1 trials in healthy adults and one phase 2 trial covering a broader age range from 18 months to 70 years have been registered.²⁶ The candidates use different platforms, including DNA-based, measles-vectored, and vesicular stomatitis virus-based approaches, reflecting the fact that researchers have not yet settled on which strategy will prove most effective against a virus with four genetically distinct lineages.

Modeling studies suggest that even a vaccine with conservative efficacy assumptions could avert substantial harm. One analysis predicted that a vaccination campaign in West Africa could prevent over 20 million dollars in lost health value and more than 128 million dollars in societal costs over a decade.²⁷ The economic case is clear, but the path from phase 2 trials to a widely deployed vaccine in rural West Africa remains long, and the infrastructure needed for cold chains and mass distribution in endemic areas is its own challenge.

The Immune Response and What Survivors Can Tell Us

People who recover from Lassa fever develop both antibody and T cell responses to the virus, and their immune profiles offer clues about protective immunity. A study comparing survivors and their exposed household contacts found that both groups had similar rates of T cell responses and binding antibodies against Lassa virus proteins. However, survivors were far more likely to have neutralizing antibodies: about 40 percent of survivors could neutralize the virus in lab tests, compared to just 6 percent of exposed contacts.²⁸ Intriguingly, none of the contacts had neutralizing antibodies against Lassa virus lineage III, a major circulating strain in Nigeria, suggesting that low-level exposure may not build the kind of broadly protective immunity that actual infection does.²⁸ For vaccine designers, the takeaway is that neutralizing antibodies may be an important correlate of protection, and a successful vaccine will likely need to elicit them across multiple lineages.

Life After Lassa Fever

Surviving Lassa fever does not mean returning to normal life. A scoping review of long-term health effects found that hearing loss remains the most common lingering problem, affecting roughly 16 to 35 percent of survivors, with over half of those also experiencing balance disorders. Beyond hearing, survivors face neurological complications including seizures (37 percent in one cohort), cognitive impairment (about 9 percent), and delayed-onset weakness in the legs. Roughly 42 percent of survivors in one study had eye problems such as cataracts and retinal hemorrhage, and depression was frequently reported.²⁹

The burden extends beyond the physical. Survivors report moderate levels of emotional distress, social avoidance, and anticipatory stigma long after they have been medically cleared. Despite being non-infectious, many find themselves distanced by community members, friends, and even family.³⁰ This is a disease that lingers in social memory. In communities where outbreaks recur, the stigma attached to having survived Lassa fever can undermine both economic stability and mental health, creating a second wave of harm that no antiviral can treat.

1
IntechOpen. A Reemerging Lassa Virus: Aspects of Its Structure, Replication, Pathogenicity and Diagnosis – Section: 2. Aspect of Lassa virus structure
2
The American Journal of Tropical Medicine and Hygiene. At Home with Mastomys and Rattus: Human-Rodent Interactions and Potential for Primary Transmission of Lassa Virus in Domestic Spaces
3
Scientific Reports. New Hosts of The Lassa Virus
4
PubMed Central. Spatio-temporal spread of Lassa virus and a new rodent host in the Mano River Union area, West Africa
5
PubMed Central. Increased Prevalence of Lassa Fever Virus-Positive Rodents and Diversity of Infected Species Found during Human Lassa Fever Epidemics in Nigeria
6
PubMed. A cluster of nosocomial Lassa fever cases in a tertiary health facility in Nigeria: Description and lessons learned, 2018
7
PubMed Central. Quantifying the seasonal drivers of transmission for Lassa fever in Nigeria
8
PubMed. Lassa Fever Natural History and Clinical Management
9
Journal of Interventional Epidemiology and Public Health. Unravelling the impact of the intersecting epidemics of Lassa fever, malaria, and arbovirus co-infections in Nigeria: A review of literature
10
Journal of Interventional Epidemiology and Public Health. Divergent pathways of severe Lassa fever: Vascular leak and hyperinflammation versus neurological disease, recommendations for therapeutic countermeasure from the pathogenesis study
11
PubMed Central. Lassa Virus Cell Entry via Dystroglycan Involves an Unusual Pathway of Macropinocytosis
12
PubMed Central. Deciphering the glycosylome of dystroglycanopathies using haploid screens for lassa virus entry
13
PubMed Central. Pathology and Pathogenesis of Lassa Fever: Novel Immunohistochemical Findings in Fatal Cases and Clinico-pathologic Correlation
14
PubMed Central. Lassa fever-induced sensorineural hearing loss: A neglected public health and social burden
15
PubMed Central. Animal Model of Sensorineural Hearing Loss Associated with Lassa Virus Infection
16
PubMed Central. Immune-Mediated Systemic Vasculitis as the Proposed Cause of Sudden-Onset Sensorineural Hearing Loss following Lassa Virus Exposure in Cynomolgus Macaques
17
PubMed Central. A prospective study of maternal and fetal outcome in acute Lassa fever infection during pregnancy
18
PubMed Central. Sensitivity and specificity of diagnostic tests for Lassa fever: a systematic review
19
PubMed. Landscape analysis of Lassa virus diagnostic tests: Challenges, innovations and future directions
20
PubMed. Lassa fever. Effective therapy with ribavirin
21
PLOS Neglected Tropical Diseases. Time to reconsider the role of ribavirin in Lassa fever
22
PubMed Central. Rodent control to fight Lassa fever: Evaluation and lessons learned from a 4-year study in Upper Guinea
23
PubMed Central. Knowledge of Lassa fever and use of infection prevention and control facilities among health care workers during Lassa fever outbreak in Ondo State, Nigeria
24
PubMed Central. Disparities in knowledge, attitude, and practices of infection prevention and control of Lassa fever among health care workers at The Federal Medical Centre, Owo, Ondo State, Nigeria
25
PLOS Neglected Tropical Diseases. Knowledge of Lassa fever, its prevention and control practices and their predictors among healthcare workers during an outbreak in Northern Nigeria: A multi-centre cross-sectional assessment
26
PubMed Central. Lassa fever vaccine candidates: A scoping review of vaccine clinical trials
27
PubMed Central. Health and economic impacts of Lassa vaccination campaigns in West Africa
28
Scientific Reports. Humoral and cellular immune responses to Lassa fever virus in Lassa fever survivors and their exposed contacts in Southern Nigeria
29
PubMed Central. Lassa fever survivors: long-term health effects and chronic sequelae – a scoping review
30
Next Research. Burden of stigmatization, perceived coping approaches and community response among Lassa fever survivors: A quantitative survey